February 21, 2017
BMS in $2 Billion accelerated share repurchase program, names 3 new directors
Bristol-Myers Squibb has entered into an ASR program with each of Morgan Stanley & Co. LLC and Goldman, Sachs & Co. to repurchase, in aggregate, $2 billion of Bristol-Myers Squibb’s common stock, and it has named three new directors.